RT Journal Article
T1 European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
A1 Nyssen, Olga P
A1 Perez-Aisa, Angeles
A1 Castro-Fernandez, Manuel
A1 Pellicano, Rinaldo
A1 Huguet, Jose M
A1 Rodrigo, Luis
A1 Ortuñ, Juan
A1 O, 
A1 Gomez-Rodriguez, Blas J
A1 Pinto, Ricardo M
A1 Areia, Miguel
A1 Perona, Monica
A1 Nuñez, Oscar
A1 Romano, Marco
A1 Gravina, Antonietta G
A1 Pozzati, Liliana
A1 Fernandez-Bermejo, Miguel
A1 Venerito, Marino
A1 Malfertheiner, Peter
A1 Fernanadez-Salazar, Luis
A1 Gasbarrini, Antonio
A1 Vaira, Dino
A1 Puig, Ignasi
A1 Megraud, Francis
A1 O'Morain, Colm
A1 Gisbert, Javier P
A1 Hp-EuReg investigators, 
K1 Helicobacter pylori
K1 Pylera
K1 bismuth
K1 eradication
K1 quadruple
AB There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation. To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy. Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile.
YR 2021
FD 2021-02-11
LK http://hdl.handle.net/10668/16588
UL http://hdl.handle.net/10668/16588
LA en
DS RISalud
RD Apr 10, 2025